Key result
Psoriatic arthritis is linked to ~5-fold higher rates of right ventricular diastolic dysfunction.
Why the study?
Psoriatic arthritis is associated with increased cardiovascular risk, but the relationship between serum monocyte chemoattractant protein-1 and echocardiographic abnormalities remained uncertain.
Do patients with psoriatic arthritis have a higher prevalence of echocardiographic ventricular dysfunction and elevated serum MCP-1 levels compared to healthy controls, and is serum MCP-1 associated with ventricular dysfunction in psoriatic arthritis?
Case-Control (n=60)
Echocardiographic measurements were obtained by one reader blinded to clinical and MCP-1 data
No
Do patients with psoriatic arthritis have a higher prevalence of echocardiographic ventricular dysfunction and elevated serum MCP-1 levels compared to healthy controls, and is serum MCP-1 associated with ventricular dysfunction in psoriatic arthritis?
Patients with psoriatic arthritis exhibit a higher prevalence of biventricular diastolic dysfunction and impaired longitudinal strain than healthy controls, though serum MCP-1 levels do not correlate with these echocardiographic abnormalities.
Serum MCP-1 should not be used to screen for cardiac dysfunction in psoriatic arthritis; leaves open which biomarkers reliably identify subclinical myocardial involvement.
Background. Psoriatic arthritis (PsA) is associated with increased cardiovascular risk, but the relationship between serum monocyte chemoattractant protein-1 (MCP-1) and echocardiographic abnormalities remains uncertain. Objective. To compare serum MCP-1 concentrations and echocardiographic findings between patients with PsA and healthy controls and, as an exploratory analysis, to examine associations between MCP-1 and ventricular dysfunction within the PsA group. Materials and methods. In this exploratory cross-sectional case-control study, 38 adults fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR) and 22 age- and sex-comparable healthy controls underwent serum MCP-1 measurement and transthoracic echocardiography. Psoriasis Area and Severity Index (PASI), Disease Activity Index for Psoriatic Arthritis (DAPSA), and Axial Spondyloarthritis Disease Activity Score (ASDAS) were assessed as applicable. Results. Patients with PsA had a higher frequency of right- and left-ventricular diastolic dysfunction than controls. Absolute ventricular longitudinal strain was reduced (values were less negative) in the PsA group. No statistically significant association was detected between MCP-1 and ventricular diastolic dysfunction, disease-activity indices, treatment category, inflammatory markers, cardiac biomarkers, or lipid measurements in the analyses presented. The ROC analysis assessed the ability of MCP-1 to discriminate between PsA cases and controls, not to predict cardiac outcomes, and showed limited discriminatory performance (AUC = 0.641; p = 0.067; 95% CI: 0.507–0.761; cutoff >58.7 ng/L; sensitivity 52.63%; specificity 63.64%). Conclusions. In this small exploratory case-control study, the PsA group showed more frequent echocardiographic abnormalities than controls. Serum MCP-1 did not demonstrate a clearly established association with those abnormalities. Longitudinal studies with adequate adjustment for cardiometabolic confounding are required before prognostic or predictive conclusions can be drawn.
No takes yet. Share an insight, caveat, or question.
Alkady et al. (2026) conducted a case-control in Psoriatic arthritis (PsA) (n=60). Psoriatic arthritis (PsA) and serum monocyte chemoattractant protein-1 (MCP-1) levels vs. Healthy controls was evaluated on Right ventricular diastolic dysfunction prevalence (p=<0.001). Psoriatic arthritis patients had higher rates of right (71.05% vs 13.64%, p<0.001) and left ventricular diastolic dysfunction than controls, without significant association with serum MCP-1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: